Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Neoplasms of the CNS

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 44 articles: HTML format

Single Articles

October 2025
1. ALHALABI OT, Klein L, Wasilewski D, Mellal A, et al
   Managing hydrocephalus in patients with leptomeningeal disease: A multicenter retrospective analysis.
   Int J Cancer. 2025;157:1613-1624.
   PubMed     Abstract available
   
   
   August 2025
2. SIGEL B, Withrow DR, Veiga LHS, Saito E, et al
   Adult brain cancer incidence patterns: A comparative study between Japan and Japanese Americans.
   Int J Cancer. 2025;157:436-444.
   PubMed     Abstract available
   
   
   July 2025
3. GALLUZZO A, Maffezzini M, Fumagalli ML, Sambruni I, et al
   The anti-aging Klotho protects glioblastoma macrophages from radiotherapy-induced inflammation and predicts immunotherapy response.
   Int J Cancer. 2025 Jul 21. doi: 10.1002/ijc.70038.
   PubMed     Abstract available
   
   
   June 2025
4. MEULENDIJKS TFC, Kaspers GJL, Ramaswamy V, Tsang DS, et al
   How long should survivors of pediatric medulloblastoma and ependymoma be screened for recurrence? A retrospective cohort study.
   Int J Cancer. 2025 Jun 23. doi: 10.1002/ijc.70016.
   PubMed     Abstract available
   
   
   
5. HEMMINGSEN CH, Kjaer SK, Hjorth S, Norby U, et al
   Maternal hormonal contraceptive use and childhood central nervous system tumor risk in a large Scandinavian cohort.
   Int J Cancer. 2025 Jun 5. doi: 10.1002/ijc.35509.
   PubMed     Abstract available
   
   
   
6. ABUHAMED J, Nikkila A, Raitanen J, Lohi O, et al
   Risk of childhood brain tumors after exposure to CT radiation: A nationwide population-based case-control study in Finland.
   Int J Cancer. 2025;156:2148-2157.
   PubMed     Abstract available
   
   
   April 2025
7. XIE Y, Fang H, Cheng W, Xu T, et al
   Furmonertinib in uncommon EGFR-mutated non-small cell lung cancer with central nervous system metastases: A retrospective cohort study.
   Int J Cancer. 2025 Apr 29. doi: 10.1002/ijc.35460.
   PubMed     Abstract available
   
   
   
8. CHELLADURAI M, Sagi-Assif O, Ben-Menachem S, Meshel T, et al
   A heterodimer of hemoglobin identifies theranostic targets on brain-metastasizing melanoma cells.
   Int J Cancer. 2025 Apr 26. doi: 10.1002/ijc.35458.
   PubMed     Abstract available
   
   
   
9. LARROQUETTE M, Bronnimann C, Ollivier M, Daubon T, et al
   Carboplatin-gemcitabine for refractory high-grade meningiomas: A study from the French national OMEGA consortium.
   Int J Cancer. 2025 Apr 21. doi: 10.1002/ijc.35453.
   PubMed     Abstract available
   
   
   
10. CHOULEUR T, Etchegaray C, Villain L, Lesur A, et al
    A strategy for multimodal integration of transcriptomics, proteomics, and radiomics data for the prediction of recurrence in patients with IDH-mutant gliomas.
    Int J Cancer. 2025 Apr 11. doi: 10.1002/ijc.35441.
    PubMed     Abstract available
    
    
    
11. HUANG T, Wu D, Jiang L, Wu Z, et al
    Neuro-astrocytic network in breast cancer brain metastases: Adaptive mechanisms and novel therapeutic targets.
    Int J Cancer. 2025 Apr 1. doi: 10.1002/ijc.35421.
    PubMed     Abstract available
    
    
    December 2024
12. CHENG S, McLaughlin JR, Brown MC, Rutka J, et al
    Birth characteristics and the risk of childhood brain tumors: A case-control study in Ontario, Canada.
    Int J Cancer. 2024 Dec 13. doi: 10.1002/ijc.35287.
    PubMed     Abstract available
    
    
    October 2024
13. 
    Expression of Concern: Betulinic Acid: A New Cytotoxic Agent Against Malignant Brain-tumor Cells.
    Int J Cancer. 2024 Oct 22. doi: 10.1002/ijc.35236.
    PubMed    
    
    
    
14. HUANGFU L, Zha B, Li P, Wang L, et al
    A phase I clinical trial of sonodynamic therapy combined with radiotherapy for brainstem gliomas.
    Int J Cancer. 2024 Oct 8. doi: 10.1002/ijc.35218.
    PubMed     Abstract available
    
    
    September 2024
15. TURUBAN M, Kromhout H, Vila J, Vallbona-Vistos M, et al
    Occupational exposure to radiofrequency electromagnetic fields and brain tumor risk: Application of the INTEROCC job-exposure matrix.
    Int J Cancer. 2024 Sep 20. doi: 10.1002/ijc.35182.
    PubMed     Abstract available
    
    
    
16. EHRET F, Ruess D, Blanck O, Fichte S, et al
    Stereotactic radiosurgery and radiotherapy for brainstem metastases: An international multicenter analysis.
    Int J Cancer. 2024;155:916-924.
    PubMed     Abstract available
    
    
    July 2024
17. 
    Expression of Concern: HOXD-AS1/miR-130a sponge regulates glioma development by targeting E2F8.
    Int J Cancer. 2024 Jul 25. doi: 10.1002/ijc.35119.
    PubMed    
    
    
    
18. ZHANG Q, Chen K, Yu X, Fan Y, et al
    Spotlight on the treatment of non-small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives.
    Int J Cancer. 2024 Jul 3. doi: 10.1002/ijc.35070.
    PubMed     Abstract available
    
    
    
19. REN P, Bao H, Wang S, Wang Y, et al
    Multi-scale brain attributes contribute to the distribution of diffuse glioma subtypes.
    Int J Cancer. 2024 Jul 1. doi: 10.1002/ijc.35068.
    PubMed     Abstract available
    
    
    June 2024
20. KNABBE J, Kowalski T, Seliger C
    Pharmacological treatment of depression in patients with brain tumors.
    Int J Cancer. 2024 Jun 28. doi: 10.1002/ijc.35058.
    PubMed     Abstract available
    
    
    
21. GANSER K, Stransky N, Abed T, Quintanilla-Martinez L, et al
    K(Ca) channel targeting impairs DNA repair and invasiveness of patient-derived glioblastoma stem cells in culture and orthotopic mouse xenografts which only in part is predictable by K(Ca) expression levels.
    Int J Cancer. 2024 Jun 27. doi: 10.1002/ijc.35064.
    PubMed     Abstract available
    
    
    
22. 
    Correction to "Inhibition of phosphatidylinositol 3-kinase signaling negates the growth advantage imparted by a mutant epidermal growth factor receptor on human glioblastoma cells".
    Int J Cancer. 2024 Jun 11. doi: 10.1002/ijc.35045.
    PubMed    
    
    
    May 2024
23. 
    Correction to "Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus".
    Int J Cancer. 2024 May 21. doi: 10.1002/ijc.35002.
    PubMed    
    
    
    
24. 
    Expression of Concern: Nusrat Jahan, Jae M. Lee, Khalid Shah, Hiroaki Wakimoto (2017), Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus. Int. J. Cancer, 141: 16
    Int J Cancer. 2024 May 21. doi: 10.1002/ijc.35032.
    PubMed     Abstract available
    
    
    
25. MEENA D, Jha S
    Autophagy in glioblastoma: A mechanistic perspective.
    Int J Cancer. 2024 May 8. doi: 10.1002/ijc.34991.
    PubMed     Abstract available
    
    
    
26. DERKS SHAE, van der Meer EL, Joosse A, de Jonge MJA, et al
    The development of brain metastases in patients with different therapeutic strategies for metastatic renal cell cancer.
    Int J Cancer. 2024 May 4. doi: 10.1002/ijc.34984.
    PubMed     Abstract available
    
    
    April 2024
27. WEIJERS DD, Hirsch S, Bakhuizen JJ, van Engelen N, et al
    Molecular analysis of cancer genomes in children with Lynch syndrome: Exploring causal associations.
    Int J Cancer. 2024;154:1455-1463.
    PubMed     Abstract available
    
    
    
28. O'NEILL K, Syed N, Crook T, Dubey S, et al
    Profiling of circulating glial cells for accurate blood-based diagnosis of glial malignancies.
    Int J Cancer. 2024;154:1298-1308.
    PubMed     Abstract available
    
    
    February 2024
29. XI S, Jiang S, Li H, Huang Q, et al
    Adult epithelioid glioblastoma exhibits an extremely poor prognosis and high frequency of SWI/SNF complex mutation: Insights from a retrospective study.
    Int J Cancer. 2024 Feb 27. doi: 10.1002/ijc.34854.
    PubMed     Abstract available
    
    
    
30. CHELLADURAI M, Xu D, Izraely S, Ben-Menachem S, et al
    A heterodimer of alpha and beta hemoglobin chains functions as an innate anticancer agent.
    Int J Cancer. 2024;154:561-572.
    PubMed     Abstract available
    
    
    January 2024
31. KEMMOTSU N, Ninomiya K, Kunimasa K, Ishino T, et al
    Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapies.
    Int J Cancer. 2024;154:169-179.
    PubMed     Abstract available
    
    
    
32. HOANG TT, Schraw JM, Peckham-Gregory EC, Scheurer ME, et al
    Fetal growth and pediatric cancer: A pan-cancer analysis in 7000 cases and 37 000 controls.
    Int J Cancer. 2024;154:41-52.
    PubMed     Abstract available
    
    
    December 2023
33. MENTIS AA, Papavassiliou KA, Piperi C, Papavassiliou AG, et al
    How can cancer research be illuminated by brain research (and vice versa)?
    Int J Cancer. 2023;153:1967-1970.
    PubMed     Abstract available
    
    
    October 2023
34. LARSEN PA, Amidi A, Ghith N, Winther JF, et al
    Quality of life of adolescent and adult survivors of childhood cancer in Europe-A systematic review.
    Int J Cancer. 2023;153:1356-1375.
    PubMed     Abstract available
    
    
    September 2023
35. SIRIRUNGREUNG A, Hansen J, Ritz B, Heck JE, et al
    Association between medically diagnosed postnatal infection and childhood cancers: A matched case-control study in Denmark, 1978 to 2016.
    Int J Cancer. 2023;153:994-1002.
    PubMed     Abstract available
    
    
    July 2023
36. PROKOP G, Wiestler B, Hieber D, Withake F, et al
    Multiscale quantification of morphological heterogeneity with creation of a predictor of longer survival in glioblastoma.
    Int J Cancer. 2023 Jul 28. doi: 10.1002/ijc.34665.
    PubMed     Abstract available
    
    
    June 2023
37. GIELNIEWSKI B, Poleszak K, Roura AJ, Szadkowska P, et al
    Targeted sequencing of cancer-related genes reveals a recurrent TOP2A variant which affects DNA binding and coincides with global transcriptional changes in glioblastoma.
    Int J Cancer. 2023 Jun 20. doi: 10.1002/ijc.34631.
    PubMed     Abstract available
    
    
    
38. TSAKONAS G, Ekman S, Koulouris A, Adderley H, et al
    Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis.
    Int J Cancer. 2023 Jun 19. doi: 10.1002/ijc.34628.
    PubMed     Abstract available
    
    
    
39. WEISS S, Thomale UW, Schulz M, Kandels D, et al
    Neurosurgical morbidity in pediatric supratentorial midline low-grade glioma: Results from the German LGG studies.
    Int J Cancer. 2023 Jun 1. doi: 10.1002/ijc.34615.
    PubMed     Abstract available
    
    
    May 2023
40. ESLIN D, Zage PE, Bergendahl G, Lewis E, et al
    A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma.
    Int J Cancer. 2023 May 29. doi: 10.1002/ijc.34569.
    PubMed     Abstract available
    
    
    
41. OFEK P, Yeini E, Arad G, Danilevsky A, et al
    Deoxyhypusine hydroxylase: A novel therapeutic target differentially expressed in short-term vs long-term survivors of glioblastoma.
    Int J Cancer. 2023 May 4. doi: 10.1002/ijc.34545.
    PubMed     Abstract available
    
    
    April 2023
42. KANNAN S, Cheng VWT
    Nanoparticle drug delivery to target breast cancer brain metastasis: Current and future trends.
    Int J Cancer. 2023 Apr 25. doi: 10.1002/ijc.34542.
    PubMed     Abstract available
    
    
    March 2023
43. BAO H, Ren P, Liang P, Liang X, et al
    Reply to: Comments on "New insights into glioma frequency maps: From genetic and transcriptomic correlate to survival prediction".
    Int J Cancer. 2023 Mar 17. doi: 10.1002/ijc.34514.
    PubMed    
    
    
    
44. SABOUR S, Ghassemi F
    Comments on "New insights into glioma frequency maps: From genetic and transcriptomic correlate to survival prediction".
    Int J Cancer. 2023 Mar 17. doi: 10.1002/ijc.34515.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge.